TrialScope Anticipates FDA Will Begin Inspecting Companies for Trial-Reporting Compliance

October 9, 2018

As seen on MedtechInsight.com - Posted Oct. 9, 2018 - Original Article

US FDA will soon ramp-up enforcement of the clinical trial transparency provisions of Title VIII of the Food and Drug Administration Amendments Act of 2007, according to TrialScope Chief Strategy Officer Thomas Wicks. Those that fall foul of these new requirements will face penalties – and it looks like SMEs will be hardest hit.


Continued on Medtech Insight

Previous Article
Five benefits to developing a global transparency policy (MedCity News)
Five benefits to developing a global transparency policy (MedCity News)

Next Article
Executive Moves: KRS, TrialScope, NVA and HERMA US
Executive Moves: KRS, TrialScope, NVA and HERMA US